You are viewing: Japan AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The Japan AI in Oncology Market was valued at $171.5 Million in 2024 and projected to reach to $858.7 Million by 2029, representing a compound annual growth rate of 30.8%. Japan's AI in Oncology market is poised for exceptional growth over the next five years, driven by the convergence of an aging population, advanced healthcare infrastructure, and substantial government backing for digital health transformation.

Japan AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan AI in Oncology Market Trends and Insights

  • This represents a compound annual growth rate of 30.8%, significantly driven by Japan's advanced healthcare infrastructure, aging population, and strong investment in digital health technologies.
  • Japan's commitment to precision medicine and early cancer detection has positioned the country as a leader in AI-enabled oncology solutions across Asia Pacific. The Japanese market benefits from robust regulatory frameworks, high healthcare spending, and collaboration between leading medical institutions and technology firms.
  • Japan's emphasis on quality of life and patient outcomes has accelerated adoption of AI diagnostic tools, treatment planning systems, and predictive analytics in oncology centers.
  • Between 2024 and 2029, Japan is expected to see increased integration of AI across clinical workflows, supported by government initiatives and private sector innovation in cancer care technology..

Key Market Statistics

  • CAGR (2024-2029) 30.8% CAGR
  • Market Size, 2024 ~USD 171.5 Million
  • Forecast, 2029 ~USD 858.7 Million
  • Country Japan

Japan AI in Oncology Market Overview

Rapid Market Expansion :

Japan's AI in Oncology market is projected to grow from $171.5 million in 2024 to $858.7 million by 2029, representing a robust 30.8% CAGR, outpacing the global average of 29.4%.

Aging Population Driving Demand :

Japan's rapidly aging demographic, with one of the world's highest life expectancies, is increasing cancer incidence rates and creating substantial demand for advanced AI-powered diagnostic and treatment solutions.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system, coupled with significant government investment in digital health and precision medicine initiatives, provides an ideal environment for AI oncology adoption and innovation.

Precision Medicine Leadership :

Japan is positioning itself as a global leader in precision oncology, with strong institutional support for AI-driven early cancer detection, personalized treatment planning, and genomic analysis technologies.

Japan AI in Oncology Market Dynamics

  • The country's commitment to precision medicine and early cancer detection aligns perfectly with AI capabilities, creating a favorable ecosystem for market expansion.
  • Healthcare providers and pharmaceutical companies are increasingly integrating AI solutions for diagnostic imaging, treatment optimization, and patient outcome prediction.
  • Regulatory support and reimbursement policies are gradually adapting to accommodate AI-based oncology solutions, further accelerating market penetration and investment..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Japan's AI in Oncology market is valued at $171.5 million in 2024 and will grow to $858.7 million by 2029 at a 30.8% CAGR.
      • Japan's aging population and advanced healthcare infrastructure are primary drivers of AI adoption in cancer diagnosis and treatment planning.
      • Japan leads Asia Pacific in precision medicine initiatives, with strong government and institutional support for AI-enabled oncology solutions.
      • Between 2024 and 2029, Japan expects significant expansion in AI diagnostic tools, predictive analytics, and personalized treatment systems.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      Japan AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      JAPAN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS10.413.917.923.230.239.351.367.288.330.4
      GOVERNMENT & REGULATORY AGENCIES4.15.46.98.811.314.518.724.131.228.6
      HEALTHCARE PAYERS2.53.44.35.67.29.412.215.920.829.9
      HEALTHCARE PROVIDERS46.963.382.3107.3140.5184.4242.7320.6424.631.5
      MEDICAL DEVICE/EQUIPMENT COMPANIES911.915.219.525.132.341.854.270.529.1
      OTHER END USERS22.63.44.35.57.1911.614.827.9
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES23.731.941.453.77091.6120.1158208.430.9
      TOTAL98.6132.5171.5222.6289.8378.5495.8651.7858.730.8

      Target Audience

      • Healthcare Technology Investors : Investors seeking high-growth opportunities in Asian healthcare markets need Japan-specific market data to evaluate investment potential, competitive dynamics, and exit opportunities in the rapidly expanding AI oncology sector.
      • Pharmaceutical & Biotech Companies : Pharma executives require detailed Japan market intelligence to assess opportunities for AI-integrated drug development, clinical trial optimization, and precision oncology partnerships with local healthcare providers.
      • Medical Device Manufacturers : Device companies need Japan-specific insights on diagnostic imaging AI adoption, regulatory requirements, and hospital procurement patterns to develop localized product strategies and distribution partnerships.
      • Healthcare IT Solution Providers : Software and IT vendors require comprehensive Japan market data to identify customer segments, understand integration requirements with Japanese healthcare systems, and plan localization strategies.
      • Hospital & Cancer Center Administrators : Healthcare facility leaders need market benchmarking data and technology trend analysis to make informed decisions about AI oncology solution adoption, budgeting, and competitive positioning within Japan's healthcare landscape.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for Japan ($171.5M in 2024) with verified 30.8% CAGR projections through 2029, enabling accurate investment decisions and competitive positioning in this high-growth market.
      • Japan-Specific Opportunity Mapping : Identify unique growth drivers specific to Japan including aging demographics, precision medicine adoption, and government digital health initiatives that differ from global market dynamics.
      • Competitive Landscape Intelligence : Understand Japan's distinct competitive environment, local player strategies, and market entry barriers to develop targeted go-to-market strategies for this premium healthcare market.
      • Regulatory & Reimbursement Insights : Access Japan-specific regulatory pathways, reimbursement policies, and healthcare system requirements essential for product commercialization and market penetration planning.
      • Strategic Investment Planning : Leverage comprehensive Japan market data to prioritize resource allocation, identify partnership opportunities, and forecast ROI for oncology AI ventures in this high-potential Asian market.

      Frequently asked questions

      What is the current size of Japan's AI in Oncology market?

      Japan's AI in Oncology market was valued at $171.5 million in 2024 and is projected to reach $858.7 million by 2029.

      What is the growth rate of Japan's AI in Oncology market?

      Japan's AI in Oncology market is growing at a compound annual growth rate (CAGR) of 30.8% from 2024 to 2029.

      What factors are driving growth in Japan's AI in Oncology market?

      Key drivers include Japan's aging population, advanced healthcare infrastructure, high healthcare spending, government precision medicine initiatives, and strong collaboration between medical institutions and technology companies.

      Which AI applications are most prevalent in Japan's oncology sector?

      Japan's oncology sector is increasingly adopting AI diagnostic tools, treatment planning systems, predictive analytics, and personalized medicine platforms for cancer care.

      How does Japan's market compare to other Asia Pacific countries?

      Japan leads Asia Pacific in AI oncology adoption due to its advanced healthcare system, regulatory maturity, high investment capacity, and strong institutional support for precision medicine.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status